April #133 : Worth a Shot - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Getting On (and off)

Kramer vs. Kramer

Mature Content




Dazed and Confused

Worth a Shot

Read My Lipids

High Definition-APRIL 2007

You Go!

Gag Reflex

Couples Therapy




Top Secret

Death in Dixie

Iraqi Pullout

And for Our Next Act...

Border Line Prevention

Almost Legal

Turning Heads

Mission Control

The Itch Is Back

Flags of a Father




Mailbox-April 2007

Catch of the Month-April 2007

Editor's Letter-April 2007



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV



email print

April 2007


Worth a Shot

by Laura Whitehorn

A vaccine against cancer-causing strains of HPV is approved only for young women. Some HIV positive men are shelling out for it anyway

There’s no getting around it: Craig Mosely (not his real name), a 43-year-old HIV positive graphic artist from Atlanta, isn’t a young woman between the ages of nine and 26. So Gardasil, the vaccine that protects against four strains of human papillomavirus (HPV), isn’t FDA-approved for him—yet. (HPV, which is sexually transmitted, can lead to cervical cancer in women and genital warts and anal cancer in both sexes.) Insurance won’t cover treatments unless they’re FDA-approved, so if Mosely wants the vax, he has to pay for it himself. Having paid $200 a shot, he’s already had two of the three that comprise an effective Gardasil safeguard. The vax may offer protection to anyone who hasn’t yet been exposed to the full quad of dangerous HPV strains, and Mosely wants Gardasil just in case. “I probably already have some HPV strains,” he says, “but the vax can keep me from getting others.”

Mark Feinberg, MD, of Merck & Co., which manufactures Gardasil, says the vax is now being tested in men (and could be ready for FDA review in 2008). He warns that Gardasil can protect only against HPV strains you haven’t already contracted; it won’t affect any strains you may already have. What’s more, tests to screen for HPV strains aren’t available outside of clinical trials.

That hasn’t stopped positive men like Mosely from getting their docs to approve the shots. While these HIV doctors agree that positive people may benefit, others, like Joel Palefsky, MD, of University of California, San Francisco, caution that studies are needed to establish the safety and effectiveness of the drug for use by positive people. Feinberg says Merck will undertake those studies—and that Gardasil’s FDA-approval doesn’t require pre-screening for HIV. (Translation: Scientists don’t foresee safety problems for positive people who get the vax). Hit the inject button.     


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.